Cyclin Dependent Kinase (CDK) Inhibitors Market
Global Cyclin Dependent Kinase (CDK) Inhibitors Market Size, Share & Trends Analysis Report by Type (Specific Inhibitors, Non-Specific Inhibitors, and Multiple Target Inhibitors), by Administration (Nasal, Oral, Intravenous, and Intramuscular), and by Application (Breast Cancer, Lymphoma, Multiple Myeloma, Ovarian Cancer, And Others) Forecast Period 2022-2028
The global cyclin dependent kinase (CDK) inhibitors market is anticipated to grow at a significant CAGR during the forecast period. The market is primarily driven by the rising incidence of cancers across the globe. Resultantly, it has increased exposure to several risk factors such as carcinogens, sedentary lifestyles, substance abuse, pollution, and others. Additionally, the growing geriatric population is another major factor that is providing various growth opportunities for the CDK inhibitors market to expand. According to the World Health Organization, the number of people aged 60 and up is expected to rise exponentially over the decade, which in turn will propel the incidence of diseases such as hypertension, diabetes, and others.
Impact of COVID-19 Pandemic on Global Cyclin Dependent Kinase (CDK) Inhibitors Market
The COVID-19 pandemic has impacted the global economy due to a slowdown in the manufacturing of various industries. As per the studies published by the WHO and National Library of Medicine, the COVID-19 (SARS-CoV-2) increased the phosphorylation of CDK2 which affects its activities and subsequently leads to cell cycle arrest, further restricting the use of CDK inhibitors for the patient diagnosed with COVID-19 infection. Thus, such factors have restrained the growth of the market during the pandemic.
Segmental Outlook
The global cyclin dependent kinase (CDK) inhibitors market is segmented based on the type, administration, and application. Based on the type, the market is segmented into specific inhibitors, non-specific or broad-range inhibitors, and multiple target inhibitors. Based on the administration, the market is sub-segmented into the nasal, oral, intravenous, and intramuscular. Based on application, the market is sub-segmented into breast cancer, lymphoma, multiple myeloma, ovarian cancer, and others. The above-mentioned segments can be customized as per the requirements. Among these, the application segment is anticipated to propel the growth of the overall market over the forecast period, owing to the rising incidences of different types of cancer globally.
Global Cyclin Dependent Kinase (CDK) Inhibitors Market Share by Type, 2021 (%)
Specific Inhibitors Segment is Anticipated to Hold a Prominent Share in the Global Cyclin Dependent Kinase (CDK) Inhibitors Market
Among the type segment, the specific inhibitors sub-segment is anticipated to hold a considerable share of the CDK inhibitors market over the forecast period. Specific inhibitors are compounds that disrupt the metabolism of one group of organisms, with little on the rest of the community. For example, the Putative specific inhibitors of SRM are used to control sulfidogenesis in industrial and engineered systems specifically. The primary factor which is driving the growth of the market is the rising inclination of the manufacturers towards adopting various R&D activities catering to expanding their existing product portfolio. For instance, in March 2021, Pfizer, Inc. initiated a Phase 1 study of a novel oral antiviral therapeutic agent against SARS-CoV-2. This is the first orally administered coronavirus-specific investigational protease inhibitor to be evaluated in clinical studies.
Regional Outlooks
The global cyclin dependent kinase (CDK) inhibitors market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. The North America region is anticipated to hold a prominent share of the market due to the strong presence of key market players in the US. However, the Asia-Pacific region is expected to grow at a significant CAGR over the forecast period owing to the rapidly emerging and expanding economies such as India, China, and others.
Global Cyclin Dependent Kinase (CDK) Inhibitors Market Growth, by Region 2022-2028
The Asia-Pacific is Expected to Hold a Prominent Share in the Global Cyclin-Dependent Kinase Market
The Asia-Pacific is anticipated to hold a prominent share in the market due to an increased purchasing power of consumers coupled with a rising preference for healthy drinks over sugary drinks and the adoption of a healthy lifestyle among individuals. Due to the growing trend, many manufacturers have started
Market Players Outlook
The major companies serving the global cyclin dependent kinase (CDK) inhibitors market include Beta Pharma, Inc., Eli Lilly & Co., FLX Bio, Inc., G1 Therapeutics Inc., Novartis Pharma AG, and Pfizer Inc., among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in December 2020, Acceleron Pharma announced that the European Commission (EC) has granted sotatercept orphan designation for the treatment of pulmonary arterial hypertension patients (PAH). Sotatercept is made available through a licensing agreement with Bristol Myers Squibb.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global cyclin dependent kinase (CDK) inhibitors market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Cyclin Dependent Kinase (CDK) Inhibitors Market
• Recovery Scenario of Global Cyclin Dependent Kinase (CDK) Inhibitors Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. BY Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Beta Pharma, Inc.
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Eli Lilly and Co.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. FLX Bio Inc.
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. G1 Therapeutics Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. Jiangsu Hengrui Medicine Co. Ltd.
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
3.7. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Cyclin Dependent Kinase (CDK) Inhibitor Market by Type
4.1.1. Specific Inhibitors
4.1.2. Non-Specific Inhibitors (Broad Range Inhibitors)
4.1.3. Multiple Target Inhibitors
4.2. Global Cyclin Dependent Kinase (CDK) Inhibitor Market by Administration
4.2.1. Nasal
4.2.2. Oral
4.2.3. Intravenous
4.2.4. Intramuscular
4.3. Global Cyclin Dependent Kinase (CDK) Inhibitor Market by Application
4.3.1. Breast Cancer
4.3.2. Lymphoma
4.3.3. Multiple Myeloma
4.3.4. Ovarian Cancer
4.3.5. Others (Cystic Fibrosis)
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Novartis Pharma AG
6.2. Onconova Therapeutics, Inc.
6.3. Pfizer Inc.
6.4. Teijin Ltd.
6.5. ViroStatics srl
6.6. Xuanzhu Biopharmaceutical Co., Ltd.
1. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL SPECIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL NON-SPECIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL MULTIPLE TARGET CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2021-2028 ($ MILLION)
6. GLOBAL NASAL FOR CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL ORAL FOR CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL INTRAVENOUS FOR CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL INTRAMUSCULAR FOR CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
11. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR BREAST CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR LYMPHOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR MULTIPLE MYELOMA MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
14. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR OVARIAN CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
16. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
17. NORTH AMERICAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
18. NORTH AMERICAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
19. NORTH AMERICAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2021-2028 ($ MILLION)
20. NORTH AMERICAN CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
21. EUROPEAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
22. EUROPEAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
23. EUROPEAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2021-2028 ($ MILLION)
24. EUROPEAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
25. ASIA-PACIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
26. ASIA-PACIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
27. ASIA-PACIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2021-2028 ($ MILLION)
28. ASIA-PACIFIC CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
29. REST OF THE WORLD CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
30. REST OF THE WORLD CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
31. REST OF THE WORLD CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY ADMINISTRATION, 2021-2028 ($ MILLION)
32. REST OF THE WORLD CYCLIN DEPENDENT KINASE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET, 2022-2028 (%)
4. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL SPECIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL NON-SPECIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL MULTIPLE TARGET CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY ADMINISTRATION, 2021 VS 2028 (%)
9. GLOBAL NASAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. GLOBAL ORAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL INTRAVENOUS CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL INTRAMUSCULAR CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
14. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR BREAST CANCER DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR LYMPHOMA DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR MULTIPLE MYELOMA DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
17. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR OVARIAN CANCER DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
18. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS FOR OTHERS DISTRIBUTION MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
19. GLOBAL CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
20. US CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
21. CANADA CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
22. UK CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
23. FRANCE CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
24. GERMANY CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
25. ITALY CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
26. SPAIN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
27. REST OF EUROPE CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
28. INDIA CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
29. CHINA CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
30. JAPAN CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
31. SOUTH KOREA CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
32. REST OF ASIA-PACIFIC CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
33. REST OF THE WORLD CYCLIN DEPENDENT KINASE (CDK) INHIBITORS MARKET SIZE, 2021-2028 ($ MILLION)
